KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Operations (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Cash from Operations data on record, last reported at 48731000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 220.68% year-over-year to 48731000.0; the TTM value through Dec 2025 reached 109836000.0, down 30.36%, while the annual FY2025 figure was 109836000.0, 30.36% down from the prior year.
  • Cash from Operations reached 48731000.0 in Q4 2025 per ACAD's latest filing, down from 74288000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 85389000.0 in Q4 2023 and bottomed at 76329000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 2228100.0, with a median of 6926000.0 recorded in 2022.
  • The widest YoY moves for Cash from Operations: up 457.97% in 2023, down 8009.35% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 23120000.0 in 2021, then fell by 3.17% to 23854000.0 in 2022, then soared by 457.97% to 85389000.0 in 2023, then tumbled by 52.71% to 40381000.0 in 2024, then plummeted by 220.68% to 48731000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 48731000.0 in Q4 2025, 74288000.0 in Q3 2025, and 63956000.0 in Q2 2025.